Stock Yearly Return 2014
Start date: 12/31/2013
End date: 12/31/2014
Start price/share: $14.99
End price/share: $9.65
Dividends collected/share: $0.00
Total return: -35.62%
Average Annual Total Return: -35.62%
Starting investment: $10,000.00
Ending investment: $6,438.00
Years: 1.00


HALO average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare HALO average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into HALO


Also see:
HALO stock yearly return 2015
HALO stock yearly return 2016
HALO stock yearly return 2017
HALO stock yearly return 2018
HALO stock yearly return 2019
HALO stock yearly return 2020
HALO YTD return
HALO average annual return 10 years
Halozyme Therapeutics is a biopharma technology platform company that provides solutions to improve patient experience and outcomes. Co.'s approved product and its collaborators' approved products and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. Co. refers to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as its ENHANZE® drug delivery technology (ENHANZE). Co. licenses the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. The HALO stock yearly return is shown above.

The yearly return on the HALO stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2014 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the HALO annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for HALO:
HALO SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Halozyme Therapeutics (HALO) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

HBIO Average Annual Return
HCA Average Annual Return
HMSY Average Annual Return
HOLX Average Annual Return
HRC Average Annual Return
HRTX Average Annual Return
HSGX Average Annual Return
HSIC Average Annual Return
HSKA Average Annual Return
HTBX Average Annual Return
More Healthcare companies »

 

HALO Stock Yearly Return 2014 | www.AverageAnnualReturn.com | Copyright © 2021 - 2021, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.